글로벌 마이코플라즈마 검사 시장 (2023-2032) : 기기, 키트 및 시약, 서비스

■ 영문 제목 : Mycoplasma Testing Market By Product (Instruments, Kits and Reagents, Services), By Technology (PCR, ELISA, Microbial Culture Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing, End of Production Cells Testing, Others), By End User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical and Biotechnology Companies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Research가 발행한 조사보고서이며, 코드는 ALD23SEP119 입니다.■ 상품코드 : ALD23SEP119
■ 조사/발행회사 : Allied Market Research
■ 발행일 : 2023년 4월
■ 페이지수 : 400
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 세계
■ 판매가격 / 옵션 (부가세 10% 별도)
Single UserUSD5,820 ⇒환산₩7,857,000견적의뢰/주문/질문
5 UserUSD6,540 ⇒환산₩8,829,000견적의뢰/주문/질문
Enterprise UserUSD9,870 ⇒환산₩13,324,500견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 마이코플라즈마 검사 시장은 2022년 0.7억 달러 규모였으며 2023년부터 2032년까지 11.7%의 연평균 성장률을 보이며 2032년에는 22억4310만 달러에 달할 것으로 예상됩니다. 마이코플라즈마 검사는 세포 배양 샘플에서 마이코플라스마 오염 여부를 감지하는 데 사용됩니다. 마이코플라스마는 세포벽이 없는 박테리아의 일종으로 세포 배양에서 검출 및 제거하기 어렵습니다. 마이코플라스마 오염은 세포 배양에서 성장 특성 변화, 유전자 발현 변화, 실험 결과 손상 등 다양한 문제를 일으킬 수 있습니다. 따라서 실험 결과의 정확성과 신뢰성을 보장하기 위해 세포 배양에 대한 마이코플라스마 오염 여부를 정기적으로 테스트하는 것이 필수적입니다. 마이코플라즈마 검사는 백신, 바이러스 배양 및 기타 바이오 의약품을 테스트하는 과정에서 중요합니다.

마이코플라즈마 검사 시장의 성장은 생물학적 제제 및 바이오시밀러에 대한 수요 증가, 세포 배양 오염의 급증, 신약 개발을 위한 새로운 기술 채택 증가에 의해 주도되고 있습니다. 생물학적 제제 및 바이오시밀러는 살아있는 세포를 사용하여 생산되는 복합 약물로, 제조 과정에서 마이코플라즈마에 의해 오염될 수 있습니다. 따라서 미국 식품의약국(FDA) 및 유럽 의약품청(EMA)과 같은 규제 기관에서는 생물학적 제제 및 바이오시밀러가 사용 승인을 받기 전에 마이코플라스마 오염 여부를 테스트하도록 요구합니다. 이로 인해 마이코플라스마 검사 서비스에 대한 수요가 급증하고 있습니다. 예를 들어, 2021년 유럽에서 바이오시밀러 경쟁의 영향에 대한 IQVIA 보고서에 따르면 2020년에 약 9개의 바이오시밀러가 승인되었고 2021년에 7개의 바이오시밀러가 승인되었습니다. 따라서 생물학적 제제 및 바이오시밀러에 대한 승인과 수요가 증가함에 따라 마이코플라스마 검사에 대한 수요도 증가했습니다.

또한 바이오 제약 산업에서 세포 배양 오염의 발생률 증가와 임상 시험의 글로벌 화는 시장 성장을 촉진하는 주요 요인입니다. 임상시험이 여러 국가와 지역에서 실시됨에 따라 임상시험 참가자의 안전과 임상시험 데이터의 정확성을 보장할 수 있는 마이코플라즈마 검사 서비스가 필요합니다. 이에 따라 표준화된 검사 요건을 충족하는 마이코플라스마 검사 서비스 및 제품에 대한 수요가 증가하고 있습니다.

그러나 마이코플라스마 검사 제품의 높은 비용으로 인해 바이오 제약 회사에서 채택이 제한되어 시장 성장이 제한되고 있습니다. 예를 들어, 세포 배양에서 마이코플라스마 오염을 검출하는 데 사용되는 서던바이오텍의 마이코플라스마 검출 키트 비용은 약 200~230달러입니다. 또한 배양 기반 마이코플라스마 검사 서비스의 가격은 샘플당 약 250-300달러입니다. 따라서 마이코플라스마 검사 제품 및 서비스의 높은 비용은 시장 성장에 부정적인 영향을 미칩니다.
반면에 미국, 독일, 중국과 같은 선진국 및 개발 도상국에서 마이코플라즈마 검사에 대한 수요가 증가함에 따라 예측 기간 동안 마이코플라즈마 검사 시장에 막대한 기회가 창출 될 것으로 예상됩니다.

마이코플라즈마 검사 시장은 제품, 기술, 애플리케이션, 최종 용도 및 지역을 기준으로 세분화됩니다. 제품을 기준으로 시장은 기기, 키트 및 시약, 서비스로 분류됩니다. 기술을 기반으로 시장은 PCR, ELISA, 미생물 배양 기술 및 효소 방법으로 나뉩니다. 응용 분야에 따라 시장은 세포주 테스트, 바이러스 테스트, 생산 종료 세포 테스트 및 기타로 분류됩니다. 최종 용도를 기준으로 시장은 학술 연구 기관, 세포 은행, 계약 연구 기관, 제약 및 생명 공학 회사 및 기타로 구분됩니다.

지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인 및 기타 유럽 지역), 아시아 태평양(중국, 일본, 인도, 호주, 한국 및 기타 아시아 태평양), 중남미/중동/아프리카(브라질, 사우디아라비아, 남아프리카공화국 및 기타 중남미/중동/아프리카)로 시장이 분석됩니다.
글로벌 마이코플라즈마 검사 시장에서 활동하는 주요 주요 업체는 ATCC, Bionique Testing Laboratories LLC, Bio-Rad Laboratories, Inc., Charles River Laboratories, Eurofins Scientific, F. Hoffmann-La Roche Ltd., InvivoGen, Lonza, Norgen Biotek Corp., and Thermo Fisher Scientific Inc. 등입니다. 시장에서 활동하는 주요 업체들은 제품 포트폴리오를 확장하기위한 주요 전략으로 제품 승인, 인수 및 제품 출시를 채택했습니다.

이해 관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 마이코플라즈마 검사 시장 분석의 시장 부문, 현재 동향, 추정 및 역학에 대한 정량적 분석을 제공하여 일반적인 마이코플라즈마 검사 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 수익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 잠재력을 강조합니다.
마이코플라스마 검사 시장 세분화에 대한 심층 분석은 지배적인 시장 기회를 파악하는데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 마이코플라스마 검사 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
제품별
기기
키트 및 시약
서비스

기술별
PCR
ELISA
미생물 배양 기법
효소 분석법

용도별
세포주 테스트
바이러스 테스트
생산 종료 세포 테스트
기타

최종 용도별
학술 연구 기관
세포 은행
계약 연구 기관
제약 및 생명공학 기업
기타

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ ATCC
○ Bionique Testing Laboratories LLC
○ Bio-Rad Laboratories, Inc. 
○ Charles River Laboratories
○ Eurofins Scientific
○ F. Hoffmann-La Roche Ltd.
○ InvivoGen
○ Lonza
○ Norgen Biotek Corp.
○ Thermo Fisher Scientific Inc. 
■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 마이코플라즈마 검사 시장, 제품별
CHAPTER 5 : 마이코플라즈마 검사 시장, 기술별
CHAPTER 6 : 마이코플라즈마 검사 시장, 응용 분야별
CHAPTER 7 : 마이코플라즈마 검사 시장, 최종 용도별
CHAPTER 8 : 마이코플라즈마 검사 시장, 지역별
CHAPTER 9 : 경쟁 현황
CHAPTER 10 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in demand for mycoplasma testing
3.4.1.2. Increase in incidences of cell culture contamination

3.4.2. Restraints
3.4.2.1. High cost of mycoplasma testing kits and instruments

3.4.3. Opportunities
3.4.3.1. Developing economies offer lucrative opportunities
3.4.3.2. Rise in technological advancements

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MYCOPLASMA TESTING MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Kits and Reagents
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Services
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: MYCOPLASMA TESTING MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. PCR
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. ELISA
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Microbial Culture Techniques
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Enzymatic Methods
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: MYCOPLASMA TESTING MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cell Line Testing
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Virus Testing
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. End of Production Cells Testing
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: MYCOPLASMA TESTING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Academic Research Institutes
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Cell Banks
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Contract Research Organizations
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
7.5. Pharmaceutical and Biotechnology Companies
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by region
7.5.3. Market share analysis by country
7.6. Others
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by region
7.6.3. Market share analysis by country
CHAPTER 8: MYCOPLASMA TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product
8.2.3. Market size and forecast, by Technology
8.2.4. Market size and forecast, by Application
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product
8.2.6.1.3. Market size and forecast, by Technology
8.2.6.1.4. Market size and forecast, by Application
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product
8.2.6.2.3. Market size and forecast, by Technology
8.2.6.2.4. Market size and forecast, by Application
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product
8.2.6.3.3. Market size and forecast, by Technology
8.2.6.3.4. Market size and forecast, by Application
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product
8.3.3. Market size and forecast, by Technology
8.3.4. Market size and forecast, by Application
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product
8.3.6.1.3. Market size and forecast, by Technology
8.3.6.1.4. Market size and forecast, by Application
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product
8.3.6.2.3. Market size and forecast, by Technology
8.3.6.2.4. Market size and forecast, by Application
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product
8.3.6.3.3. Market size and forecast, by Technology
8.3.6.3.4. Market size and forecast, by Application
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product
8.3.6.4.3. Market size and forecast, by Technology
8.3.6.4.4. Market size and forecast, by Application
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product
8.3.6.5.3. Market size and forecast, by Technology
8.3.6.5.4. Market size and forecast, by Application
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product
8.3.6.6.3. Market size and forecast, by Technology
8.3.6.6.4. Market size and forecast, by Application
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product
8.4.3. Market size and forecast, by Technology
8.4.4. Market size and forecast, by Application
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product
8.4.6.1.3. Market size and forecast, by Technology
8.4.6.1.4. Market size and forecast, by Application
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product
8.4.6.2.3. Market size and forecast, by Technology
8.4.6.2.4. Market size and forecast, by Application
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product
8.4.6.3.3. Market size and forecast, by Technology
8.4.6.3.4. Market size and forecast, by Application
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product
8.4.6.4.3. Market size and forecast, by Technology
8.4.6.4.4. Market size and forecast, by Application
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product
8.4.6.5.3. Market size and forecast, by Technology
8.4.6.5.4. Market size and forecast, by Application
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product
8.4.6.6.3. Market size and forecast, by Technology
8.4.6.6.4. Market size and forecast, by Application
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product
8.5.3. Market size and forecast, by Technology
8.5.4. Market size and forecast, by Application
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product
8.5.6.1.3. Market size and forecast, by Technology
8.5.6.1.4. Market size and forecast, by Application
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product
8.5.6.2.3. Market size and forecast, by Technology
8.5.6.2.4. Market size and forecast, by Application
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product
8.5.6.3.3. Market size and forecast, by Technology
8.5.6.3.4. Market size and forecast, by Application
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product
8.5.6.4.3. Market size and forecast, by Technology
8.5.6.4.4. Market size and forecast, by Application
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Thermo Fisher Scientific Inc. 
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Charles River Laboratories
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Lonza
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. F. Hoffmann-La Roche Ltd.
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bio-Rad Laboratories, Inc. 
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Eurofins Scientific
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. ATCC
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Bionique Testing Laboratories LLC
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.9. InvivoGen
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.10. Norgen Biotek Corp.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MYCOPLASMA TESTING MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 06. MYCOPLASMA TESTING MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
TABLE 07. MYCOPLASMA TESTING MARKET FOR ELISA, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 11. MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 14. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 20. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. MYCOPLASMA TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 27. U.S. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 28. U.S. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 29. U.S. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. U.S. MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 31. CANADA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 32. CANADA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 33. CANADA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. CANADA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 35. MEXICO MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 36. MEXICO MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 37. MEXICO MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. MEXICO MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 40. EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 41. EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. EUROPE MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 44. GERMANY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 45. GERMANY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 46. GERMANY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. GERMANY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. FRANCE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 49. FRANCE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 50. FRANCE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. FRANCE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. UK MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 53. UK MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 54. UK MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. UK MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 56. ITALY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 57. ITALY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 58. ITALY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. ITALY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 60. SPAIN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 61. SPAIN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 62. SPAIN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. SPAIN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 66. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 73. JAPAN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 74. JAPAN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 75. JAPAN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. JAPAN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. CHINA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. CHINA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 79. CHINA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. CHINA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 81. AUSTRALIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 82. AUSTRALIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 85. INDIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 86. INDIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 87. INDIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. INDIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 90. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 91. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 97. LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 98. LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 99. LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 100. LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 101. LAMEA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 102. BRAZIL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 103. BRAZIL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 104. BRAZIL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. BRAZIL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 111. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 112. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 113. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 115. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 116. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 117. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 118. THERMO FISHER SCIENTIFIC INC. : KEY EXECUTIVES
TABLE 119. THERMO FISHER SCIENTIFIC INC. : COMPANY SNAPSHOT
TABLE 120. THERMO FISHER SCIENTIFIC INC. : PRODUCT SEGMENTS
TABLE 121. THERMO FISHER SCIENTIFIC INC. : SERVICE SEGMENTS
TABLE 122. THERMO FISHER SCIENTIFIC INC. : PRODUCT PORTFOLIO
TABLE 123. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
TABLE 124. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 125. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
TABLE 126. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
TABLE 127. LONZA: KEY EXECUTIVES
TABLE 128. LONZA: COMPANY SNAPSHOT
TABLE 129. LONZA: PRODUCT SEGMENTS
TABLE 130. LONZA: SERVICE SEGMENTS
TABLE 131. LONZA: PRODUCT PORTFOLIO
TABLE 132. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 133. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 134. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 135. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 136. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 137. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 138. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 139. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 140. EUROFINS SCIENTIFIC: KEY EXECUTIVES
TABLE 141. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 142. EUROFINS SCIENTIFIC: SERVICE SEGMENTS
TABLE 143. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 144. ATCC: KEY EXECUTIVES
TABLE 145. ATCC: COMPANY SNAPSHOT
TABLE 146. ATCC: PRODUCT SEGMENTS
TABLE 147. ATCC: SERVICE SEGMENTS
TABLE 148. ATCC: PRODUCT PORTFOLIO
TABLE 149. BIONIQUE TESTING LABORATORIES LLC: KEY EXECUTIVES
TABLE 150. BIONIQUE TESTING LABORATORIES LLC: COMPANY SNAPSHOT
TABLE 151. BIONIQUE TESTING LABORATORIES LLC: PRODUCT SEGMENTS
TABLE 152. BIONIQUE TESTING LABORATORIES LLC: SERVICE SEGMENTS
TABLE 153. BIONIQUE TESTING LABORATORIES LLC: PRODUCT PORTFOLIO
TABLE 154. INVIVOGEN: KEY EXECUTIVES
TABLE 155. INVIVOGEN: COMPANY SNAPSHOT
TABLE 156. INVIVOGEN: PRODUCT SEGMENTS
TABLE 157. INVIVOGEN: SERVICE SEGMENTS
TABLE 158. INVIVOGEN: PRODUCT PORTFOLIO
TABLE 159. NORGEN BIOTEK CORP.: KEY EXECUTIVES
TABLE 160. NORGEN BIOTEK CORP.: COMPANY SNAPSHOT
TABLE 161. NORGEN BIOTEK CORP.: PRODUCT SEGMENTS
TABLE 162. NORGEN BIOTEK CORP.: SERVICE SEGMENTS
TABLE 163. NORGEN BIOTEK CORP.: PRODUCT PORTFOLIO
※본 조사보고서 [글로벌 마이코플라즈마 검사 시장 (2023-2032) : 기기, 키트 및 시약, 서비스] (코드 : ALD23SEP119) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 마이코플라즈마 검사 시장 (2023-2032) : 기기, 키트 및 시약, 서비스] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!